PanTera, a joint venture between IBA and SCK CEN in Belgium, has signed an agreement with Bayer to supply actinium-225 starting in the second half of 2024. This partnership reflects PanTera's position as a reliable EU-based supplier of 225Ac. The company plans to increase access to 225Ac for clinical trials and develop a large-scale production facility to meet global demand. CEO Sven Van den Berghe believes that PanTera's ability to supply 225Ac will advance research and clinical trials in the field, supporting the pharmaceutical industry in the fight against cancer.
Mol, Belgium - PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 ( 225Ac) starting in the second half of 2024.
This first agreement with a major drug developer reflects PanTera’s unique position to be a reliable, EU-based supplier of 225Ac from this year onward. In 2024, PanTera will continue to work on increasing access to 225Ac for clinical trial needs, as well as on the development of a large-scale, state-of-the-art production facility to address growing global demand.
Sven Van den Berghe, CEO of PanTera, commented, “PanTera’s emerging ability to start supplying 225Ac this year will allow research and clinical trials in this domain to advance. The combined expertise and technology from SCK CEN and IBA places PanTera in a unique position to become the go-to global supplier of 225Ac for (pre-)clinical trials and commercial use. PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics in the fight against cancer.”